{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:40:15Z","timestamp":1728866415226},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma and is characterized by heterogeneity in biology and clinical behavior. Mutations in the myeloid differentiation primary response 88 (MYD88) are found in different lymphoproliferative disorders and are associated with variable clinical and prognostic impact.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To investigate the frequency of <jats:italic>MYD88 L265P<\/jats:italic> mutation and its clinical impact in a cohort of Egyptian DLBCL patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>FFPE lymph node samples from 87 DLBCL patients (46 males \/ 41 females; median age, 58\u00a0years) were included and analyzed for MYD88 L265P by an allele-specific PCR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p><jats:italic>MYD88<\/jats:italic> L265P mutations were found in 52 patients (59.8%) out of 87 DLBCL cases. Patients with L265 mutation were significantly younger than non-mutated patients (<jats:italic>p<\/jats:italic>\u2009=\u20090.022). None of the patients with the L265P mutation showed a significant association with the clinical parameters of DLBCL. Interestingly, MYD88 L265 mutated patients were found to be significantly correlated with HCV infection (<jats:italic>p<\/jats:italic>\u2009=\u20090.037). The median follow-up time across the entire cohort was 26\u00a0months. Univariate analysis showed that overall survival (OS) was affected by gender, LDH level, and CNS-IPI scoring (<jats:italic>p<\/jats:italic>\u2009=\u20090.048, 0.008, and 0.046, respectively), while disease-free survival (DFS) was affected by B symptoms and LDH level (<jats:italic>p<\/jats:italic>\u2009=\u2009\u2009&lt;\u20090.000 and 0.02, respectively). However, the MYD88 mutation status and other prognostic factors showed no association with OS or DFS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings indicate a high frequency of <jats:italic>MYD88<\/jats:italic> L265P mutations in our study population and not associated with prognostic markers or the outcome of the disease.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43046-024-00237-z","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:01:53Z","timestamp":1728864113000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utility of clinical, laboratory, and lymph node MYD88 L265P mutation in risk assessment of diffuse large B-cell lymphoma patients"],"prefix":"10.1186","volume":"36","author":[{"given":"Ahmed Talaat","family":"Hanbal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaimaa","family":"El-Ashwah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed E.","family":"Eladl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameh","family":"Shamaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Layla M.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"issue":"6769","key":"237_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503\u201311.","journal-title":"Nature"},{"key":"237_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0065-2776(05)87005-1","volume":"87","author":"LM Staudt","year":"2005","unstructured":"Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol. 2005;87:163\u2013208.","journal-title":"Adv Immunol"},{"issue":"1","key":"237_CR3","first-page":"5","volume":"9","author":"KC Thandra","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin\u2019s lymphoma. Med Sci (Basel, Switzerland). 2021;9(1):5.","journal-title":"Med Sci (Basel, Switzerland)"},{"issue":"2","key":"237_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/2394-4722.156767","volume":"1","author":"Y Sallam","year":"2015","unstructured":"Sallam Y, Gaber A, Shaheen A, Zeeneldin A. Non-anthracycline chemotherapy associated with a poor outcome in elderly Egyptian patients with diffuse large B-cell non-Hodgkin lymphoma. J Cancer Metastasis Treatment. 2015;1(2):76.","journal-title":"J Cancer Metastasis Treatment"},{"issue":"13","key":"237_CR5","doi-asserted-by":"publisher","first-page":"22014","DOI":"10.18632\/oncotarget.15782","volume":"8","author":"N Yoon","year":"2017","unstructured":"Yoon N, Ahn S, Yoo HY, Kim SJ, Kim WS, Ko YH. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm. Oncotarget. 2017;8(13):22014\u201322.","journal-title":"Oncotarget"},{"issue":"12","key":"237_CR6","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","volume":"194","author":"RE Davis","year":"2001","unstructured":"Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor \u03baB activity is required for survival of activated B cell\u2013like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861\u201374.","journal-title":"J Exp Med"},{"issue":"5","key":"237_CR7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1182\/blood-2017-12-819706","volume":"132","author":"C Boudesco","year":"2018","unstructured":"Boudesco C, Verhoeyen E, Martin L, Chassagne-Clement C, Salmi L, Mhaidly R, et al. HSP110 sustains chronic NF-\u03baB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization. Blood. 2018;132(5):510\u201320.","journal-title":"Blood"},{"issue":"7247","key":"237_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature07968","volume":"459","author":"M Compagno","year":"2009","unstructured":"Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NF-\u03baB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717\u201321.","journal-title":"Nature"},{"issue":"5","key":"237_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373\u201384.","journal-title":"Nat Immunol"},{"issue":"1","key":"237_CR10","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/s41598-017-01998-5","volume":"7","author":"JH Lee","year":"2017","unstructured":"Lee JH, Jeong H, Choi JW, Oh HE, Kim YS. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis. Sci Rep. 2017;7(1):1785.","journal-title":"Sci Rep"},{"issue":"7332","key":"237_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115\u201321.","journal-title":"Nature"},{"issue":"4","key":"237_CR12","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1073\/pnas.1205299110","volume":"110","author":"J Zhang","year":"2013","unstructured":"Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci. 2013;110(4):1398\u2013403.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"237_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/gcc.22126","volume":"53","author":"E Bohers","year":"2014","unstructured":"Bohers E, Mareschal S, Bouzelfen A, Marchand V, Ruminy P, Maingonnat C, et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosom Cancer. 2014;53(2):144\u201353.","journal-title":"Genes Chromosom Cancer"},{"issue":"19","key":"237_CR14","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","volume":"18","author":"A Gonzalez-Aguilar","year":"2012","unstructured":"Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012;18(19):5203\u201311.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"237_CR15","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1038\/jid.2012.102","volume":"132","author":"A Pham-Ledard","year":"2012","unstructured":"Pham-Ledard A, Cappellen D, Martinez F, Vergier B, Beylot-Barry M, Merlio JP. MYD88 Somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Investig Dermatol. 2012;132(8):2118\u201320.","journal-title":"J Investig Dermatol"},{"issue":"10","key":"237_CR16","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/leu.2014.184","volume":"28","author":"C Fern\u00e1ndez-Rodr\u00edguez","year":"2014","unstructured":"Fern\u00e1ndez-Rodr\u00edguez C, Bellosillo B, Garc\u00eda-Garc\u00eda M, S\u00e1nchez-Gonz\u00e1lez B, Gimeno E, Vela MC, et al. MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma. Leukemia. 2014;28(10):2104\u20136.","journal-title":"Leukemia"},{"issue":"20","key":"237_CR17","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"14","key":"237_CR18","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","volume":"28","author":"M Ziepert","year":"2010","unstructured":"Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373\u201380.","journal-title":"J Clin Oncol"},{"issue":"1","key":"237_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jnci.2011.07.003","volume":"23","author":"T Abdelhamid","year":"2011","unstructured":"Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study. J Egypt Natl Canc Inst. 2011;23(1):17\u201324.","journal-title":"J Egypt Natl Canc Inst"},{"issue":"5","key":"237_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"},{"issue":"1","key":"237_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275\u201382.","journal-title":"Blood"},{"issue":"11","key":"237_CR22","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","volume":"121","author":"L Xu","year":"2013","unstructured":"Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, et al. MYD88 L265P in Waldenstr\u00f6m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051\u20138.","journal-title":"Blood"},{"issue":"24","key":"237_CR23","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1182\/blood-2013-12-543306","volume":"123","author":"A Mart\u00ednez-Trillos","year":"2014","unstructured":"Mart\u00ednez-Trillos A, Pinyol M, Navarro A, Aymerich M, Jares P, Juan M, et al. Regular Article LYMPHOID NEOPLASIA Mutations in TLR\/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood. 2014;123(24):3790\u20136.","journal-title":"Blood"},{"issue":"11","key":"237_CR24","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s00262-018-2242-9","volume":"67","author":"ANR Weber","year":"2018","unstructured":"Weber ANR, Cardona Gloria Y, \u00c7\u0131nar \u00d6, Reinhardt HC, Pezzutto A, Wolz OO. Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities. Cancer Immunol Immunother. 2018;67(11):1797\u2013807.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"237_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/bjh.13369","volume":"171","author":"AM Staiger","year":"2015","unstructured":"Staiger AM, Ott MM, Parmentier S, Rosenwald A, Ott G, Horn H, et al. Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples. Br J Haematol. 2015;171(1):145\u20138.","journal-title":"Br J Haematol"},{"issue":"11","key":"237_CR26","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1158\/1078-0432.CCR-15-1525","volume":"22","author":"J Rovira","year":"2016","unstructured":"Rovira J, Karube K, Valera A, Colomer D, Enjuanes A, Colomo L, et al. MYD88 L265P mutations, but no other variants, identify a subpopulation of DLBCL patients of activated B-cell origin, extranodal involvement, and poor outcome. Clin Cancer Res. 2016;22(11):2755\u201364.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"237_CR27","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1038\/bcj.2013.28","volume":"3","author":"W Kraan","year":"2013","unstructured":"Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJM, Oud MECM, Scheepstra C, et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J. 2013;3(9):e139\u2013e139.","journal-title":"Blood Cancer J"},{"issue":"3","key":"237_CR28","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.humpath.2013.10.023","volume":"45","author":"Y Kim","year":"2014","unstructured":"Kim Y, Ju H, Kim DH, Yoo HY, Kim SJ, Kim WS, et al. CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Hum Pathol. 2014;45(3):556\u201364.","journal-title":"Hum Pathol"},{"issue":"7","key":"237_CR29","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1089\/gtmb.2015.0041","volume":"19","author":"V Caner","year":"2015","unstructured":"Caner V, Sen Turk N, Baris IC, Cetin GO, Tepeli E, Hacioglu S, et al. MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas. Genet Test Mol Biomarkers. 2015;19(7):372\u20138.","journal-title":"Genet Test Mol Biomarkers"},{"issue":"2","key":"237_CR30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3324\/haematol.2018.214122","volume":"105","author":"JS Vermaat","year":"2020","unstructured":"Vermaat JS, Somers SF, De Wreede LC, Kraan W, De Groen RAL, Schrader AMR, et al. MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. Haematologica. 2020;105(2):424\u201334.","journal-title":"Haematologica"},{"issue":"2","key":"237_CR31","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3892\/mmr.2020.11186","volume":"22","author":"J Niu","year":"2020","unstructured":"Niu J, Ma Z, Nuerlan A, Li S, Cui W, Gao H, et al. Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR. Mol Med Rep. 2020;22(2):1243\u201356.","journal-title":"Mol Med Rep"},{"key":"237_CR32","doi-asserted-by":"publisher","unstructured":"Yu S, Luo H, Pan M, Palomino LA, Song X, Wu P, et al. High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment. Oncol Lett. 2018;15(2):1707\u201315. https:\/\/doi.org\/10.3892\/ol.2017.7472. Epub 2017 Nov 22.","DOI":"10.3892\/ol.2017.7472"},{"issue":"7","key":"237_CR33","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.humpath.2012.10.026","volume":"44","author":"JW Choi","year":"2013","unstructured":"Choi JW, Kim Y, Lee JH, Kim YS. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Hum Pathol. 2013;44(7):1375\u201381.","journal-title":"Hum Pathol"},{"key":"237_CR34","doi-asserted-by":"crossref","unstructured":"Fogliatto L, Grokoski KC, Strey YM, Vanelli T, Fraga CG da S, Barra MB, et al. Prognostic impact of MYD88 mutation, proliferative index and cell origin in diffuse large B cell lymphoma. Hematol Transfus Cell Ther. 2019;41(1):50\u20136.","DOI":"10.1016\/j.htct.2018.05.014"},{"issue":"10","key":"237_CR35","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-18-0215","volume":"78","author":"X Yu","year":"2018","unstructured":"Yu X, Li W, Deng Q, Li L, Hsi ED, Young KH, et al. MYD88 L265P mutation in lymphoid malignancies. Can Res. 2018;78(10):2457\u201362.","journal-title":"Can Res"},{"issue":"3","key":"237_CR36","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bjh.14080","volume":"177","author":"K Hattori","year":"2017","unstructured":"Hattori K, Sakata-Yanagimoto M, Okoshi Y, Goshima Y, Yanagimoto S, Nakamoto-Matsubara R, et al. MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma. Br J Haematol. 2017;177(3):492\u20134.","journal-title":"Br J Haematol"},{"issue":"2","key":"237_CR37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3960\/jslrt.56.71","volume":"56","author":"A Dobashi","year":"2016","unstructured":"Dobashi A. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Exp Hematop. 2016;56(2):71\u20138.","journal-title":"J Clin Exp Hematop"},{"issue":"6","key":"237_CR38","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1086\/655812","volume":"202","author":"H Chung","year":"2010","unstructured":"Chung H, Watanabe T, Kudo M, Chiba T. Hepatitis C virus core protein induces homotolerance and cross-tolerance to toll-like receptor ligands by activation of toll-like receptor 2. J Infect Dis. 2010;202(6):853\u201361.","journal-title":"J Infect Dis"},{"issue":"1","key":"237_CR39","doi-asserted-by":"publisher","first-page":"e2019011","DOI":"10.4084\/mjhid.2019.011","volume":"11","author":"LM Saleh","year":"2019","unstructured":"Saleh LM, Canioni D, Shamaa S, El-Zaafarany M, Emarah Z, Abdel-Aziz S, et al. High prevalence of Hepatitis C virus associated B-cell lymphoma in Mansoura Region (Egypt), ANRS 12263 study. Mediterr J Hematol Infect Dis. 2019;11(1):e2019011.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"34","key":"237_CR40","doi-asserted-by":"publisher","first-page":"23620","DOI":"10.18632\/oncotarget.25306","volume":"9","author":"C Keane","year":"2018","unstructured":"Keane C, Tobin J, Talaulikar D, Green M, Crooks P, Jain S, et al. A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival. Oncotarget. 2018;9(34):23620\u20137.","journal-title":"Oncotarget"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-024-00237-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-024-00237-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-024-00237-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:03:13Z","timestamp":1728864193000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-024-00237-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["237"],"URL":"https:\/\/doi.org\/10.1186\/s43046-024-00237-z","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"assertion":[{"value":"8 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study was approved by the institutional review board of the Faculty of Medicine, Mansoura University, Egypt.\u00a0Written informed consent was obtained from all participants in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}